Rosuvastatin attenuates contrast-induced nephropathy through modulation of nitric oxide, inflammatory responses, oxidative stress and apoptosis in diabetic male rats

[1]  Suraj Khanal.  Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. , 2014 .

[2]  S. Villani,et al.  Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). , 2014, Journal of the American College of Cardiology.

[3]  M. Alpert.  Do statins reduce the risk of contrast-induced acute kidney injury in patients undergoing coronary angiography or percutaneous coronary interventions? , 2014, Journal of the American College of Cardiology.

[4]  M. Khamaisi,et al.  Why Is Diabetes Mellitus a Risk Factor for Contrast-Induced Nephropathy? , 2013, BioMed research international.

[5]  B. Tomlinson,et al.  Current Perspectives on rosuvastatin , 2013, Integrated blood pressure control.

[6]  S. Norgren,et al.  Tetramethylpyrazine Prevents Contrast-Induced Nephropathy by Inhibiting p38 MAPK and FoxO1 Signaling Pathways , 2013, American Journal of Nephrology.

[7]  A. L. Jorgensen.  Contrast-induced nephropathy: pathophysiology and preventive strategies. , 2013, Critical care nurse.

[8]  Wu-chang Yang,et al.  Gene Polymorphisms of Interleukin-10 and Tumor Necrosis Factor-α Are Associated with Contrast-Induced Nephropathy , 2013, American Journal of Nephrology.

[9]  S. M. Lee,et al.  Rosuvastatin Attenuates Inflammation, Apoptosis and Fibrosis in a Rat Model of Cyclosporine-Induced Nephropathy , 2012, American Journal of Nephrology.

[10]  A. Colombo,et al.  Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury , 2012, Circulation.

[11]  G. Marenzi,et al.  Contrast-induced nephropathy , 2012, Internal and Emergency Medicine.

[12]  A. Al-Asmari,et al.  Simvastatin Attenuates Contrast-Induced Nephropathy through Modulation of Oxidative Stress, Proinflammatory Myeloperoxidase, and Nitric Oxide , 2012, Oxidative medicine and cellular longevity.

[13]  F. Dal-Pizzol,et al.  Sodium butyrate decreases the activation of NF-κB reducing inflammation and oxidative damage in the kidney of rats subjected to contrast-induced nephropathy. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  Cheuk-Kwan Sun,et al.  Continuing Exposure to Low-Dose Nonylphenol Aggravates Adenine-Induced Chronic Renal Dysfunction and Role of Rosuvastatin Therapy , 2012, Journal of Translational Medicine.

[15]  F. Cakalagaoglu,et al.  Effect of the Direct Renin Inhibitor Aliskiren in the Prevention of Experimental Contrast-Induced Nephropathy in the Rat , 2012, Kidney and Blood Pressure Research.

[16]  Mina Kim,et al.  Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats , 2012, Toxicology mechanisms and methods.

[17]  E. Mazzon,et al.  Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. , 2012, European journal of pharmacology.

[18]  A. Hall,et al.  Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease , 2012, Clinical Medicine Insights. Cardiology.

[19]  W. Yuan,et al.  Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. , 2011, Clinical nephrology.

[20]  S. Stavrakis,et al.  Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis. , 2011, International journal of cardiology.

[21]  N. Raposo,et al.  Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide–deficient rats , 2011, Clinics.

[22]  G. Troncone,et al.  In vivo and in vitro assessment of pathways involved in contrast media-induced renal cells apoptosis , 2011, Cell Death and Disease.

[23]  Linghong Shen,et al.  Statins for the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis , 2011, American Journal of Nephrology.

[24]  S. Misra,et al.  Contrast-induced acute kidney injury and diabetic nephropathy , 2010, Nature Reviews Nephrology.

[25]  W. Romanowski,et al.  Serum interleukin-6 concentration predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. , 2010, European cytokine network.

[26]  M. Khamaisi,et al.  Reactive Oxygen Species and the Pathogenesis of Radiocontrast-Induced Nephropathy , 2010, Investigative radiology.

[27]  S. Norgren,et al.  N-Acetylcysteine Amide Protects Renal Proximal Tubular Epithelial Cells against Iohexol-Induced Apoptosis by Blocking p38 MAPK and iNOS Signaling , 2009, American Journal of Nephrology.

[28]  A. Deev,et al.  Contrast-induced nephropathy in patients with type 2 diabetes during coronary angiography: risk-factors and prognostic value. , 2009, Diabetes research and clinical practice.

[29]  E. Bae,et al.  Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  M. Rudnick,et al.  Clinical significance and preventive strategies for contrast-induced nephropathy , 2008, Current opinion in nephrology and hypertension.

[31]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[32]  L. Rochette,et al.  Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats , 2008, Free radical research.

[33]  M. Sipahioğlu,et al.  Preventive effect of nebivolol on contrast-induced nephropathy in rats. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  R. Muniyappa,et al.  Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. , 2007, Endocrinology.

[35]  G. Remuzzi,et al.  Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. , 2007, The American journal of pathology.

[36]  S. Matetzky,et al.  Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies , 2005, Canadian Medical Association Journal.

[37]  G. Stone,et al.  A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. , 2004, Journal of the American College of Cardiology.

[38]  C. Baker.  Prevention of radiocontrast‐induced nephropathy , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[39]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[40]  V. Lauta,et al.  Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. , 2001, Cytokine.

[41]  P. Jansen,et al.  Nitrite and nitrate determinations in plasma: a critical evaluation. , 1995, Clinical chemistry.

[42]  A. Thomson,et al.  Circulating proinflammatory cytokines (IL‐1β, TNF‐α, and IL‐6) and IL‐1 receptor antagonist (IL‐1Ra) in fulminant hepatic failure and acute hepatitis , 1994 .

[43]  M. Ozkaraca,et al.  Protective effect of curcumin against contrast induced nephropathy in rat kidney: what is happening to oxidative stress, inflammation, autophagy and apoptosis? , 2014, European review for medical and pharmacological sciences.

[44]  C. Tseng,et al.  Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. , 2013, The review of diabetic studies : RDS.

[45]  P. Holvoet.  Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. , 2008, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

[46]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[47]  A. Thomson,et al.  Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. , 1994, Clinical and experimental immunology.

[48]  L. Packer,et al.  Oxidative damage to proteins: spectrophotometric method for carbonyl assay. , 1994, Methods in enzymology.